-transparent.png){kind=logo}
Experiments on rats showed that 14-day exposure of the animals to pyrazinamide in a dose of 1.5 g/kg induced marked disorders in cholopoiesis and lowering of the reduced glutathion levels in the liver. When pyrazinamide was used in combination with isoniazid or rifampicin a marked increase in the activity of aspartate and alanine aminotransferases in blood serum and induction of lipid peroxidation in the liver were observed in addition to the disorders in cholopoiesis and lowering of the reduced glutathion levels. Combined use of pyraxinamide, isoniazid and rifampicin induced disorders in the liver state not differing significantly from those observed with using pyrazinamide in combination with isoniazid or rifampicin.
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
October 2002,
International journal of clinical pharmacology and therapeutics,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
December 1988,
Bulletin of the International Union against Tuberculosis and Lung Disease,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
October 1998,
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
April 1990,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
January 2014,
PloS one,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
September 2007,
Biopharmaceutics & drug disposition,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
November 2007,
Biopharmaceutics & drug disposition,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
February 1996,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
June 1993,
Schweizerische medizinische Wochenschrift,
Iu I Slivka, and
E V Klimniuk, and
O E Tabachuk
January 1989,
Farmakologiia i toksikologiia,
